论文部分内容阅读
目的探讨血清β2微球蛋白(β2-MG)和CD4+CD25+CD127low/-调节性T细胞(regulatoryTcells,Treg)在非霍奇金淋巴瘤(NHL)中的临床意义。方法对67例非霍奇金淋巴瘤患者按骨髓涂片检查结果分为淋巴瘤白血病组,有骨髓侵润组和无骨髓侵润组。40例健康体检者为对照组。用AU2700全自动生化分析仪分别对其血清进行β2-MG进行检测,同时用流式细胞仪检测外周血CD4+CD25+CD127low/-调节性T细胞表达百分率。结果①非霍奇金淋巴瘤患者的血清β2-MG水平明显高于对照组(P<0.01),其中淋巴瘤白血病组和有骨髓侵润组β2-MG水平高于无骨髓侵润组(P<0.01);淋巴瘤白血病组高于骨髓侵润组(P<0.01).3组非霍奇金淋巴瘤患者化疗后β2-MG水平均低于化疗前的水平(P<0.05)。②非霍奇金淋巴瘤患者、健康对照组外周血CD4+CD25+CD127low/-调节性T细胞占CD4+淋巴细胞的比例分别为6.73±1.79%、4.15±1.43%。非霍奇金淋巴瘤患者Treg细胞表达高于健康对照组,差异有显著性(P<0.05);淋巴瘤白血病组和有骨髓侵润组Treg细胞表达比例明显高于无骨髓侵润组(P<0.05),疾病越严重,Treg细胞表达水平越高;非霍奇金淋巴瘤患者化疗前外周血CD4+CD25+CD127low/-调节性T细胞水平升高,化疗后外周血Treg细胞水平降低,结论血清β2微球蛋白和CD4+CD25+CD127low/-调节性T细胞检测对非霍奇金淋巴瘤的诊断,疗效及预后的判断具有重要的临床价值。
Objective To investigate the clinical significance of serum β2 microglobulin (β2-MG) and CD4 + CD25 + CD127low / - regulatory T cells (Tregs) in non-Hodgkin’s lymphoma (NHL). Methods 67 patients with non-Hodgkin’s lymphoma according to the results of bone marrow smear were divided into lymphoma leukemia group, with bone marrow infiltration and non-marrow infiltration group. 40 healthy people as control group. The serum was detected by AU2700 biochemical analyzer, and the percentage of CD4 + CD25 + CD127low / - regulatory T cells in peripheral blood was detected by flow cytometry. Results ① The level of β2-MG in non-Hodgkin’s lymphoma patients was significantly higher than that in the control group (P <0.01). The level of β2-MG in lymphoma leukemia group and myeloid infiltration group was higher than that in non-Hodgkin lymphoma group <0.01). The levels of β2-MG in 3 non-Hodgkin’s lymphoma patients after chemotherapy were lower than those before chemotherapy (P <0.05). ② In non-Hodgkin’s lymphoma patients, the percentage of CD4 + CD25 + CD127low / - regulatory T cells in CD4 + lymphocytes in peripheral blood of healthy controls were 6.73 ± 1.79% and 4.15 ± 1.43%, respectively. The expression of Treg cells in non-Hodgkin’s lymphoma patients was significantly higher than that in healthy controls (P <0.05). The expression of Treg cells in lymphoma leukemia patients and those with bone marrow infiltration was significantly higher than that in non-Hodgkin’s lymphoma patients <0.05). The more severe the disease, the higher the expression of Treg cells. The levels of CD4 + CD25 + CD127low / - regulatory T cells in peripheral blood of patients with non-Hodgkin’s lymphoma increased after chemotherapy and the levels of Treg cells in peripheral blood decreased after chemotherapy. Conclusion Serum β2-microglobulin and CD4 + CD25 + CD127low / - regulatory T cells have important clinical value in the diagnosis, treatment and prognosis of non-Hodgkin’s lymphoma.